• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Insufficient evidence for treatments of myalgic encephalomyelitis/chronic fatigue syndrome

byKenan Celtik, MSandSai Folmsbee
June 16, 2015
in Chronic Disease
Reading Time: 2 mins read
Unclear if medical therapy management improves health outcomes
Share on FacebookShare on Twitter

1. From a systematic review of myalgic encephalomyelitis/chronic fatigue syndrome (ME-CFS) symptom relief, most treatments showed inconclusive or no statistically significant benefits.

2. In mostly fair-quality trials, rintatolimod, valganciclovir, and CBT were linked to mild improvements in ME-CFS symptoms.

Evidence Rating Level: 2 (Good)

Study Rundown: Myalgic encephalomyelitis/chronic fatigue syndrome (ME-CFS), defined by post-exertional malaise and changes in memory or concentration, is a poorly understood debilitating condition of unknown cause. This systematic review evaluated ME-CFS treatment trials of at least 12 weeks duration. Most treatments, including galantamine, hydrocortisone, IgG, isoprinosine, fluoxetine, diets, phototherapy, supplements, qigong exercise, graded exercise therapy (GET) and distant healing (prayer), showed inconclusive or no statistically significant benefit when compared to usual care or placebo. Valganciclovir, counseling, and behavioral therapy were potentially associated with mild improvements in fatigue symptoms. Rintatolimod improved activities of daily living and exercise performance and duration, but was associated with flu-like symptoms. A variety of counseling and behavioral therapies showed improved fatigue, physical function, quality of life and work impairment, but were too different to allow for comparison across therapies. Cognitive behavioral therapy (CBT) was linked to significant improvements in physical function, but one meta-analysis on CBT showed no significant benefit in physical function. Harms were poorly reported across all studies. This study was limited by the lack of high-quality trials using comparable outcomes, methods and baseline groups. Overall, it is clear that better evidence is needed to assess effective treatments for ME-CFS.

Click to read the study, published today in the Annals of Internal Medicine

Relevant Reading: Treatment Outcome and Metacognitive Change in CBT and GET for Chronic Fatigue Syndrome

RELATED REPORTS

In phase 3 trial, rituximab not associated with clinical improvement in patients with Myalgic encephalomyelitis/chronic fatigue syndrome

Anakinra not linked to reduction in fatigue severity in women with chronic fatigue syndrome

In-Depth [systematic-review]: This systematic review of the treatment for ME-CFS included 9 medication trials, 7 complementary and alternative medicine trials, 14 counseling and behavioral therapy trials and 4 mixed trials. The trials were mostly fair- (24 trials) and poor-quality (5 trials), with many being underpowered (n <20), dissimilar baseline groups, high loss to follow-up, poor randomization or inadequate blinding. There are currently no FDA approved therapies for ME-CFS. Of the off-label medications used to treat ME-CFS, only rintatolimod and valganciclovir showed benefit. Rintatolimod improved exercise tolerance (36.5% v. 15.2%, p=0.047) and improved exercise work (11.8% v. 5.8%, p=0.01). Seven trials (quality: 1 good, 5 fair, 1 poor) of alternative/complementary medicines and dietary supplements showed no benefit when compared to usual care. CBT was linked to improved physical function (mean weighted difference 10.46, CI -7.47 to 27.77, P=0.002). Graded exercise therapy showed no statistically significant improvements in physical function and clinical global impression of change score.

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: chronic fatigue syndrome
Previous Post

Arterial recanalization may not indicate reperfusion in ischemic stroke

Next Post

Patient diet choices not associated with improved weight loss

RelatedReports

Quick Take: Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
Chronic Disease

In phase 3 trial, rituximab not associated with clinical improvement in patients with Myalgic encephalomyelitis/chronic fatigue syndrome

April 5, 2019
Shared decision-making tool for antidepressants improves patient and physician satisfaction
Chronic Disease

Anakinra not linked to reduction in fatigue severity in women with chronic fatigue syndrome

March 22, 2017
Next Post
Motivational interviewing and dietary counseling reduce BMI

Patient diet choices not associated with improved weight loss

Pediatric cardiac surgery occurring at earlier age, with better outcomes over 50+ year review

Antibiotics fail to meet noninferior threshold compared to surgery in uncomplicated acute appendicitis

Multicomponent nonpharmacological delirium intervention reduced delirium, falls

Multidisciplinary teams may not improve outcomes on general medicine wards

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Molecularly guided therapy may improve outcomes in patients with unfavourable cancer of unknown primary compared with standard chemotherapy
  • Methadone initiation linked to lower mortality compared to buprenorphine-naloxone after opioid overdose
  • Continuous femoral nerve block is not superior to continuous adductor canal block for postoperative pain following ACL reconstruction
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.

2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in